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ABSTRACT:
(S)-Warfarin 7-hydroxylation and midazolam 1-hydroxylation are
among the preferred probe substrate reactions for CYP2C9 and
CYP3A4/5, respectively. The impact of solvents on enzyme activity,
kinetic parameters, and predicted in vivo hepatic clearance (ClH)
associated with each reaction has not been evaluated. The effects
of increasing concentrations [0.1–2% (v/v)] of six organic solvents
(acetonitrile, methanol, ethanol, dimethyl sulfoxide, acetone, iso-
propanol) were first tested on each reaction using human liver
microsomes (HLMs), human intestinal microsomes (midazolam 1-
hydroxylation only), and recombinant enzymes. Across enzyme
sources, relative to water, acetonitrile and methanol had the least
inhibitory effect on (S)-warfarin 7-hydroxylation (0–58 and 9–96%,
respectively); acetonitrile, methanol, and ethanol had the least
inhibitory effect on midazolam 1-hydroxylation (0–29, 0–22, and
0–20%, respectively). Using HLMs, both acetonitrile and methanol
(0.1–2%) decreased the Vmax (32–60 and 24–65%, respectively)
whereas methanol (2%) increased the Km (100%) of (S)-warfarin-
hydroxylation. (S)-Warfarin ClH was underpredicted by 21–65%
(acetonitrile) and 13–84% (methanol). Acetonitrile, methanol, and
ethanol had minimal to modest impact on both the kinetics of
midazolam 1-hydroxylation (10–24%) and predicted midazolam
ClH (2–20%). In conclusion, either acetonitrile or methanol at
<0.1% is recommended as the primary organic solvent for the
(S)-warfarin 7-hydroxylation reaction; acetonitrile is preferred if
higher solvent concentrations are required. Acetonitrile, methanol,
and ethanol at <2% are recommended as primary organic solvents
for the midazolam 1-hydroxylation reaction. This information
should facilitate optimization of experimental conditions and im-
prove the interpretation and accuracy of in vitro-in vivo predictions
involving these two preferred cytochrome P450 probe substrate
reactions.
Introduction
Organic solvents often are required to solubilize xenobiotics for the
purpose of characterizing metabolic pathways and evaluating drug
interaction liabilities in vitro. It has been recognized since at least the
late 1960s that an organic solvent can modulate enzymatic activity. A
study published in 1980 evaluated the effects of nine water-miscible
organic solvents on different mixed-function oxidase activities, in-
cluding benzo[a]pyrene hydroxylation, 7-ethyoxycoumarin O-deethy-
lation, aminopyrine N-demethylation, p-nitroanisole O-demethyl-
ation, and aniline hydroxylation (Kawalek and Andrews, 1980).
Different solvents had different effects on a given reaction. Several of
the substrates used are now known to be metabolized by one or more
cytochrome P450 (P450) enzymes. In the late 1990s, the effects of
different solvents on probe substrate reactions for a number of drug-
metabolizing P450s were examined (Draper et al., 1997; Chauret et
al., 1998; Hickman et al., 1998; Busby et al., 1999; Tang et al., 2000).
Scientists at the U.S. Food and Drug Administration subsequently
compiled information from these latter reports to recommend assay
conditions for in vitro drug interaction studies, in which any solvent
causing 20% inhibition was considered acceptable (Yuan et al.,
2002). The recommendations highlighted a critical lack of information
regarding solvent effects on (S)-warfarin 7-hydroxylation and mida-
zolam 1-hydroxylation, preferred probe reactions for CYP2C9 and
CYP3A4/5, respectively. After a decade, insufficient information
remains regarding selection of an organic solvent that will least
confound interpretation of in vitro P450 inhibition studies involving
either of these reactions.
Increasing reports have substantiated earlier observations that the
inhibitory effect of a xenobiotic on enzymatic activity can vary with
substrate. One report comparing the effects of 34 pharmaceutical
agents on the metabolism of 10 CYP3A4/5 substrates demonstrated
that the substrates could be clustered into three distinct subgroups
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(Kenworthy et al., 1999). Midazolam, testosterone, and nifedipine
were considered representative substrates of such subgroups and have
been postulated to bind to different domains within the enzyme active
site, at least for CYP3A4 (Kenworthy et al., 1999; Schrag and Wie-
nkers, 2001). Likewise, CYP2C9 substrates have been shown to
cluster into three distinct subgroups, one of which was represented by
diclofenac, tolbutamide, and phenytoin; the remaining two subgroups
were represented by (S)-warfarin and (S)-flurbiprofen (Kumar et al.,
2006a). Taken together, more than one probe substrate may be re-
quired to evaluate fully the inhibitory potential of a given xenobiotic
on the activity of either enzyme. The recommendation of using more
than one probe substrate for CYP2C9 and CYP3A4/5 underscores
further the importance of filling the knowledge gap regarding solvent
effects on the aforementioned (S)-warfarin and midazolam hydroxy-
lation reactions.
The goal of the current work was to provide a comprehensive
evaluation of the effects of organic solvents on CYP2C9-mediated
(S)-warfarin 7-hydroxylation and CYP3A4/5-mediated midazolam 1-
hydroxylation. The first objective was to test the inhibitory potential
of six commonly used solvents (acetonitrile, methanol, ethanol,
DMSO, acetone, isopropanol) on each reaction using human intestinal
and/or liver microsomes and recombinant P450 enzymes. The second
objective was to examine the effects of the least inhibitory solvents on
the kinetics of each reaction [(S)-warfarin 7-hydroxylation: acetoni-
trile, methanol; midazolam 1-hydroxylation: acetonitrile, methanol,
ethanol] using human liver microsomes (HLMs). The third objective
was to assess the impact of the least inhibitory solvents on the
predicted in vivo hepatic plasma clearance (ClH) of each substrate.
This rigorous approach provided critical information for optimizing
experimental conditions and for improving the interpretation and
accuracy of in vitro-in vivo predictions involving (S)-warfarin and
midazolam as probe substrates.
Materials and Methods
Chemicals and Reagents. (S)-Warfarin; 7-hydroxywarfarin; midazolam;
1-hydroxymidazolam; alprazolam; and baculovirus-insect cell-expressed
CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP3A4, and CYP3A5 (supplemented
with cDNA-expressed reductase but not cytochrome b5) were purchased from
BD Biosciences (San Jose, CA). HLMs (pooled from 50 donors, mixed gender)
were purchased from XenoTech, LLC (Lenexa, KS). Human intestinal micro-
somes (HIMs) were prepared previously from mucosal scrapings from the
jejunal portion of a donor small intestine representing average CYP3A4/5
protein expression and activity (midazolam 1-hydroxylation) (Paine et al.,
2006). Methanol (liquid chromatography/mass spectrometry grade) and ace-
tonitrile, acetone, and isopropanol (high-performance liquid chromatography
grade) were purchased from Thermo Fisher Scientific (Waltham, MA). Etha-
nol (190 proof) was purchased from Decon Labs (King of Prussia, PA). DMSO
(spectrophotometric grade) was purchased from Acros Organics (Fairlawn,
NJ). Chlorowarfarin, ketoconazole, sulfaphenazole, and NADPH were pur-
chased from Sigma-Aldrich (St. Louis, MO). All other chemicals were ana-
lytical grade or higher.
Incubation Conditions. Initial testing. Incubation mixtures consisted of
microsomes or recombinant enzyme, substrate, test solvent or water (control),
and potassium phosphate buffer (100 mM, pH 7.4). Although CYP2C9 and
CYP3A4/5 are expressed appreciably in both the human intestine and liver
(Paine et al., 2006), intestinal CYP2C9 has not yet been shown to have a
significant impact on drug disposition in vivo. As such, solvent effects on
(S)-warfarin 7-hydroxylation in HIMs were not examined. Each solvent was
diluted in buffer to yield working concentrations of 0.4, 4, or 8% (v/v).
(S)-Warfarin, midazolam, sulfaphenazole, and ketoconazole were dissolved in
methanol to yield a working concentration of 10 mM, 8 mM, 1 mM, and 200
M, respectively. NADPH was prepared fresh in buffer to yield a working
concentration of 4 mM. Incubation mixtures were prepared in 96-well plates
and equilibrated at 37°C in a solid heat block for 5 min before initiating
reactions with NADPH (1 mM final concentration), yielding a final volume of
200 l. (S)-Warfarin 7-hydroxylation reaction mixtures consisted of HLMs
(0.1 mg/ml) or rCYP2C9 (12.5 pmol/ml), (S)-warfarin (4 M), test solvent
(0.1, 1, or 2%), and buffer. After 30 min (HLMs, CYP2C9*1, CYP2C9*2) or
60 min (CYP2C9*3), reactions were terminated with 200 l of cold methanol
containing the internal standard, chlorowarfarin (3.3 nM). Midazolam 1-
hydroxylation reaction mixtures consisted of HLMs (0.05 mg/ml), HIMs (0.1
mg/ml), or rCYP3A4/5 (10 pmol/ml); midazolam (4 M); test solvent (0.1, 1,
or 2%); and buffer supplemented with magnesium chloride (3.3 mM). After 2
min (HLMs) or 4 min (HIMs, rCYP3A4/5), reactions were terminated with
200 l of cold acetonitrile containing the internal standard, alprazolam (65
nM). As a positive control for CYP2C9 and CYP3A4/5 inhibition, mixtures
contained sulfaphenazole (1 M) or ketoconazole (1 M), respectively, in
place of test solvent. Control mixtures contained water in place of test solvent.
After centrifugation (1350g for 10 min at 4°C), the supernatant (8 l) was
analyzed by high-performance liquid chromatography/tandem mass spectrom-
etry as described previously for 7-hydroxywarfarin (Brantley et al., 2010; Ngo
et al., 2010) or 1-hydroxymidazolam (Wang et al., 2007; Ngo et al., 2009).
The amount of 7-hydroxywarfarin or 1-hydroxymidazolam formed in all
enzyme sources was linear with respect to both incubation time and protein
concentration (Wang et al., 2007; Ngo et al., 2009; Brantley et al., 2010), the
latter of which was optimized to mitigate nonspecific binding concerns (data
not shown).
Determination of enzyme kinetics. The effects of selected solvents on
(S)-warfarin 7- and midazolam 1-hydroxylation kinetics were evaluated using
HLMs. Incubation conditions were identical to those described for initial
testing except that a range of substrate concentrations was used (1–15 and
0.63–10 M for (S)-warfarin and midazolam, respectively).
Data Analysis. Initial estimates of apparent enzyme kinetic parameters, Km
and Vmax, were obtained from Eadie-Hofstee plots (velocity versus velocity/
[substrate]). Final estimates were obtained by fitting the Michaelis-Menten (eq.
1) or Hill (eq. 2) equation to [substrate] versus velocity data using WinNonlin











where v represents velocity of metabolite formation, S represents nominal
substrate concentration, S50 represents substrate concentration corresponding
to 50% of Vmax, and n represents the Hill coefficient. Goodness of fit was
assessed from visual inspection of the observed versus predicted data, ran-
domness of the residuals, Akaike information criteria, and S.E.s of the param-
eter estimates.
Hepatic microsomal intrinsic clearance (Clint) was calculated as the ratio of
Vmax to Km. The analogous term for substrates described by the Hill equation,
maximum clearance (Clmax) (Houston and Galetin, 2008), was calculated as
follows:
CImax 
Vmax  n  1
S50  nn  1
1/n (3)
Clint or Clmax was scaled to whole-liver intrinsic clearance (Clint,liver) or
whole-liver maximum intrinsic clearance (Clmax,liver) using scaling factors of
45 mg of microsomal protein/g liver and 20 g of liver/kg body weight (Obach
et al., 1997). Predicted in vivo hepatic plasma clearance (ClH) was calculated
using the well-stirred model:
CIH 
Qp  fu 
CIint,liver
fm




where Qp represents hepatic plasma flow (11 ml  min
1  kg1), assuming a
hematocrit of 0.45 (Yang et al., 2007); fu represents the unbound fraction of
substrate in plasma (0.01 and 0.02 for warfarin and midazolam, respectively)
(O’Reilly, 1972; Thummel et al., 1996; Gorski et al., 1998; Obach, 1999); and
fm represents the fraction of substrate clearance forming the metabolite (0.45
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and 0.70 for 7-hydroxywarfarin and 1-hydroxymidazolam, respectively) (Chan et al.,
1994; Thummel et al., 1996; Gorski et al., 1998; Takahashi et al., 1999).
Statistical Analysis. Data were analyzed statistically using SigmaStat (ver-
sion 3.5; Systat Software, Inc., San Jose, CA). If the amount of metabolite
formed was below the limit of quantification, a value one-half the lowest
calibration standard (0.04 and 1.0 pmol for 7-hydroxywarfarin and 1-hydroxy-
midazolam, respectively) was assigned. If the amount of metabolite formed
was below the limit of detection, a value of zero was assigned. Concentration-
dependent inhibition by a given solvent in each enzyme source was evaluated
by one-way analysis of variance (ANOVA); post hoc comparisons were made
using Tukey’s test when an overall difference resulted (p  0.05). Enzyme
kinetic parameters are presented as estimates  S.E.s. Between-concentration
differences in enzyme kinetic parameters for a given solvent were evaluated by
one-way ANOVA; post hoc comparisons were made using Tukey’s test when
an overall difference resulted (p  0.05).
Results
Initial Testing of Solvents on CYP2C9 and CYP3A4/5 Probe
Substrate Reactions. (S)-Warfarin 7-hydroxylation. The tested sol-
vents differentially inhibited (S)-warfarin 7-hydroxylation in HLMs
and rCYP2C9s (Fig. 1). Relative to water, acetonitrile and methanol
at the lowest concentration examined (0.1%) demonstrated 20%
inhibition in all enzyme sources except rCYP2C9*1 (24 and 21%,
respectively). Acetone at 0.1% demonstrated 20% inhibition in
HLMs and rCYP2C9*3 but not rCYP2C9*1 (32%) and rCYP2C9*2
(30%). The remaining solvents at 0.1% demonstrated 	20% inhibi-
tion in all enzyme sources, from 23% by DMSO in rCYP2C9*3 to
58% by isopropanol in HLMs. Acetonitrile at 1 and 2% inhibited
activity by 35–40% and 38–58%, respectively. The remaining sol-
vents at 1 and 2% inhibited activity by 	51 and 	62%, respectively.
The CYP2C9 inhibitor, sulfaphenazole, inhibited activity by 	75% in
all enzyme sources. Midazolam 1-Hydroxylation. The tested solvents
differentially inhibited midazolam 1-hydroxylation in HLMs, HIMs,
and rCYP3As (Fig. 2). Relative to water, methanol and ethanol had
the least inhibitory effects, demonstrating 20% inhibition in all
enzyme sources, and at all concentrations examined, except methanol
at 2% in HIMs (22%). Acetonitrile demonstrated 20% inhibition in
all enzyme sources except HLMs at the highest concentration tested
(29%). DMSO, acetone, and isopropanol at 0.1% demonstrated 20%
inhibition in all enzyme sources except DMSO in HIMs (29%) and
acetone in rCYP3A4 (36%). These three solvents at higher concen-
trations demonstrated more variable and generally a greater extent of
inhibition (23–83%) compared with methanol, ethanol, and acetoni-
trile. The inhibition profile of DMSO was distinct, showing a signif-
icant stepwise pattern. Acetone and isopropanol were the least con-
sistent among enzyme sources; both solvents inhibited activity in
HLMs and rCYP3A4 to a greater extent than activity in HIMs and
rCYP3A5, with acetone showing particularly pronounced differential
effects. The CYP3A inhibitor, ketoconazole, inhibited activity by
85% in all enzyme sources except rCYP3A5 (62%).
Effects of Selected Solvents on CYP2C9 and CYP3A Probe
Substrate Reaction Kinetics in HLMs. (S)-Warfarin 7-hydroxyla-
tion. Based on initial testing (Fig. 1), acetonitrile and methanol were
selected for further evaluation. Eadie-Hofstee plots for both solvents
at all concentrations examined suggested a unienzyme system (Fig. 3,
A and B). The data were described best by the simple Michaelis-
Menten equation (eq. 1) (Fig. 3, C and D). Relative to water, aceto-
nitrile had no significant effect on Km but decreased Vmax progres-
sively, by 32–60%, with increasing concentrations (Table 1).
FIG. 1. Screen of the inhibitory potential of organic solvents, relative to control
(water), on (S)-warfarin 7-hydroxylation activity HLMs and rCYP2C9 enzymes.
Control activities were 4.1  0.2 pmol  min1  mg1 in pooled HLMs and 15 
0.6, 10  0.6, and 3.5  0.1 pmol  min1  nmol1 in rCYP2C9*1, rCYP2C9*2,
and rCYP2C9*3, respectively. Bars denote means of triplicate incubations. Error
bars denote S.D.s of triplicate incubations. , p  0.05 versus 0.1%; #, p  0.05
versus 1% (one-way ANOVA, followed by Tukey’s test).
FIG. 2. Screen of the inhibitory potential of organic solvents, relative to control
(water), on midazolam 1-hydroxylation activity in HLMs, HIMs, and rCYP3A
enzymes. Control activities were 0.95  0.05 nmol  min1  mg1 in pooled HLMs,
0.47  0.02 nmol  min1  mg1 in HIMs, and 2.1  0.2 and 2.7  0.1 nmol 
min1  nmol1 in rCYP3A4 and rCYP3A5, respectively. Bars denote means of
triplicate incubations. Error bars denote S.D.s of triplicate incubations. , p  0.05
versus 0.1%; #, p  0.05 versus 1% (one-way ANOVA, followed by Tukey’s test).
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Methanol had no significant effect on Km at concentrations 1% but
nearly doubled Km at a concentration of 2%. Similar to acetonitrile,
methanol decreased Vmax progressively, by 24 to 65%, with increasing
concentrations.
Midazolam 1-hydroxylation. Based on initial testing (Fig. 2),
acetonitrile, methanol, and ethanol were selected for further eval-
uation. Eadie-Hofstee plots of all three solvents at all concentra-
tions examined showed a characteristic “hook,” indicative of au-
toactivation (Fig. 4, A–C) (Houston et al., 2003). The data were
described best by the Hill equation (eq. 2) (Fig. 4, D–F); Hill
coefficients ranged from 1.3 to 1.6 (S.E.s 0.10). Relative to
water, all three solvents had no significant effect on either S50 or
Vmax regardless of concentration (Table 1).
Effects of Selected Solvents on Predicted Hepatic Plasma Clear-
ance of (S)-Warfarin and Midazolam. (S)-Warfarin. Relative to
water, acetonitrile at 0.1% had a modest effect (21% decrease) on ClH,
whereas the higher concentrations decreased ClH by 52–65% (Table
1). Similar to acetonitrile, methanol at 0.1% had a modest effect (13%
decrease) on predicted ClH, whereas the higher concentrations de-
creased ClH by 58–84% (Table 1).
Midazolam. Relative to water, all three solvents (acetonitrile, meth-
anol, ethanol) at all concentrations examined had a negligible to
modest effect (20%) on ClH (Table 1).
Discussion
The potential for organic solvents to modulate in vitro catalytic
activity of drug-metabolizing enzymes has been recognized for de-
cades. Such enzymes include CYP2C9 and CYP3A4/5, which com-
bined are involved in the oxidative metabolism of more than 50% of
marketed drugs (Wienkers and Heath, 2005; Zanger et al., 2008). In
addition, more than one probe substrate has been recommended for
drug interaction studies involving either enzyme (Kenworthy et al.,
1999; Kumar et al., 2006a). Despite these observations and recom-
mendations, a lack of comprehensive information remains regarding
selection of an optimal organic solvent for one of the preferred probe
substrate reactions for each enzyme, specifically (S)-warfarin 7-hy-
droxylation (CYP2C9) and midazolam 1-hydroxylation (CYP3A4/
5). This deficiency has been addressed in the current evaluation of the
effects of common solvents on each reaction in HLMs and/or HIMs
and recombinant P450 enzymes.
FIG. 3. Effects of organic solvents on the kinetics of 7-hydroxy-
warfarin formation in HLMs. Eadie-Hofstee (A and B) and Michae-
lis-Menten (C and D) plots depict 7-hydroxywarfarin formation in
the presence of water and 0.1, 1, or 2% (v/v) of either acetonitrile
(ACN) (A and C) or methanol (MeOH) (B and D). Symbols denote
observed values. Curves denote model-generated values. Error bars
denote S.D.s of triplicate incubations.
TABLE 1
Effects of selected solvents on the kinetic parameters of (S)-warfarin and midazolam hydroxylation in HLMs
(S)-Warfarin 7-Hydroxylation Midazolam 1-Hydroxylation
Km Vmax Clint,liver ClH S50 Vmax Clmax,liver ClH
M pmol  min1  mg1 ml  min1  kg1 M nmol  min1  mg1 ml  min1  kg1
Water 6.8  0.7 10.7  0.7 3.1 0.031 3.7  0.6 2.8  0.3 550 5.5
Acetonitrile
0.1% 5.8  0.6 7.3  0.4* 2.5 0.025 2.3  0.2 2.5  0.1 720 6.2
1% 7.7  0.9 5.9  0.5† 1.5 0.015 4.7  0.7‡ 2.9  0.3 440 4.9
2% 7.8  0.9 4.3  0.4†,‡ 1.1 0.011 4.3  0.4 2.2  0.1 360 4.4
Methanol
0.1% 5.9  0.6 8.1  0.5* 2.7 0.027 3.1  0.3 2.4  0.1 520 5.4
1% 7.9  0.9 4.9  0.4†,‡ 1.3 0.013 3.3  0.4 2.3  0.2 480 5.1
2% 13.8  1.6*,‡,§ 3.7  0.3†,‡ 0.54 0.005 4.3  0.7 2.5  0.3 400 4.6
Ethanol
0.1% 3.8  0.4 3.2  0.2 600 5.8
1% 4.9  0.6 3.7  0.3 550 5.5
2% 5.5  0.6 3.5  0.3 460 5.0
Clint,liver, whole-liver intrinsic clearance; Clmax,liver, whole-liver maximum intrinsic clearance; ClH, predicted in vivo hepatic plasma clearance.
* P  0.050 versus water (one-way ANOVA, followed by Tukey’s test).
† P  0.001 versus water (one-way ANOVA, followed by Tukey’s test).
‡ P  0.050 versus 0.1% (one-way ANOVA, followed by Tukey’s test).
§ P  0.050 versus 1% (one-way ANOVA, followed by Tukey’s test).
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As anticipated, different solvents differentially inhibited both probe
substrate reactions. Initial testing showed that the effect of a given
solvent varied with concentration and enzyme source. An ideal sol-
vent should have no inhibitory effect on enzyme activity. However,
because solubility limitations are commonplace for lipophilic mole-
cules, 20% inhibition or less has been deemed acceptable (Yuan et al.,
2002). This criterion was used to assess effects of the various solvents.
Acetonitrile and methanol at the lowest concentration examined
(0.1%) inhibited (S)-warfarin 7-hydroxylation by 20% in all enzyme
sources except rCYP2C9*1 (24 and 21%, respectively). At the higher
concentrations tested (1 and 2%), acetonitrile had the least inhibitory
effect, ranging from 35 to 40% and from 38 to 58%, respectively.
Previous studies examining effects of multiple solvents on CYP2C9
activity, all published before 2002, used tolbutamide or diclofenac as
the probe substrate and a single enzyme source (HLMs, human
hepatocytes, or recombinant enzyme) (Chauret et al., 1998; Hickman
et al., 1998; Busby et al., 1999; Tang et al., 2000; Easterbrook et al.,
2001). Consistent with current observations, acetonitrile had the least
inhibitory effect on both tolbutamide 4-hydroxylation (HLMs, human
hepatocytes) and diclofenac 4-hydroxylation (rCYP2C9) at all tested
concentrations, which ranged from 0.1 to 5%. However, the extent of
inhibition (5%) was typically much less than that of (S)-warfarin
7-hydroxylation, even at the lowest concentration examined. The
increased sensitivity of (S)-warfarin compared with these other
CYP2C9 substrates could reflect different experimental conditions
and/or inherent differences in substrate access/binding to the enzyme
active site, as discussed later.
Compared with (S)-warfarin 7-hydroxylation, midazolam 1-hy-
droxylation was more resilient to the solvents. Methanol, ethanol, and
acetonitrile demonstrated 20% inhibition in all enzyme sources
except methanol at 2% in HIMs (22%) and acetonitrile at 2% in
HLMs (29%). Most of the aforementioned pre-2002 studies examined
solvent effects on CYP3A4/5 activity using testosterone as the probe
substrate. Consistent with current observations, methanol (HLMs,
human hepatocytes, rCYP3A4) and ethanol (rCYP3A4) at concentra-
tions 2% had the least inhibitory effect on testosterone 6-hydroxy-
lation (15 and 5%, respectively) (Chauret et al., 1998; Busby et
al., 1999; Easterbrook et al., 2001). Acetonitrile at 1% tended to
have a slightly greater effect, inhibiting activity in HLMs by up to
25% (Chauret et al., 1998; Busby et al., 1999; Easterbrook et al.,
2001). To the authors’ knowledge, only one previous study examined
effects of solvents on CYP3A4/5 activity using midazolam as the
probe substrate (Iwase et al., 2006). Using HLMs only, acetonitrile,
methanol, and ethanol inhibited activity by 5%. These lower extents
of inhibition compared with current observations may be attributable
to the lower solvent concentrations tested (0.1–1%), higher substrate
and microsomal protein concentrations (10 M and 0.5 mg/ml, re-
spectively), and/or longer incubation time (10 min). Nevertheless, the
relative resilience of both midazolam 1-hydroxylation and testoster-
one 6-hydroxylation to the tested solvents, along with the notion that
midazolam and testosterone belong to different CYP3A4/5 substrate
subgroups (Kenworthy et al., 1999), was not unexpected given the
promiscuous and flexible nature of CYP3A4 (Otyepka et al., 2012).
The solvents that showed the least inhibitory effects upon initial
testing were evaluated further on the enzyme kinetics of each reaction
in HLMs. Acetonitrile and methanol were selected for (S)-warfarin
7-hydroxylation; acetonitrile, methanol, and ethanol were selected for
midazolam 1-hydroxylation. Under control (water) conditions, Km
(or S50) and Vmax values were in close agreement with previous
reports for both reactions (Rettie et al., 1988; Thummel et al., 1996;
von Moltke et al., 1996; Kumar et al., 2006b; Isoherranen et al., 2008),
allowing generalization of results among laboratories. The Km of
7-hydroxywarfarin formation remained relatively constant (6–8 M),
whereas Vmax decreased (11 to 4 pmol  mg
1  min1), with increas-
ing concentrations of acetonitrile and methanol (0.1–1%), suggesting
noncompetitive inhibition. These observations are consistent with the
effects of acetonitrile on the kinetics of the CYP2C9-mediated hy-
droxylation of celecoxib (Tang et al., 2000). Only the highest con-
centration of methanol (2%) altered the Km of 7-hydroxywarfarin
formation significantly (14 M). The increased Km, coupled with a
decreased Vmax, suggests mixed-type inhibition, which has not been
reported previously for any CYP2C9 probe reaction. In contrast to
(S)-warfarin 7-hydroxylation, none of the tested solvents significantly
altered the Km and Vmax of midazolam 1-hydroxylation. These dif-
ferential effects highlight further the differences between CYP2C9
and CYP3A4 in terms of flexibility and promiscuity, as well as the
CYP2C9 substrate-dependent sensitivity to the tested solvents.
ClH for (S)-warfarin under control conditions was near the range of
values reported from clinical studies (0.031 versus 0.031–0.061 ml 
min1  kg1) (Abernethy et al., 1991; Heimark et al., 1992; Chan et
al., 1994; McAleer et al., 1997; Takahashi et al., 1999; Ngo et al.,
2010). This improved in vitro-in vivo concordance compared with a
previous report (Obach, 1999) may reflect use of intrinsic formation
clearance of the metabolite, rather than in vitro half-life of the sub-
strate, and the lack of need to incorporate nonspecific binding because
of the much lower microsomal protein concentration (0.1 versus 3
mg/ml) (Obach et al., 1997). Although blood clearance is the preferred
measure of drug clearance, incorporation of liver plasma flow and
plasma unbound fraction permitted direct comparison with reported in
vivo plasma clearance values. Consistent with initial testing, acetoni-
trile or methanol at 0.1% did not impact (S)-warfarin ClH by more
FIG. 4. Effects of organic solvents on the kinetics of 1 hydroxymidazolam forma-
tion in HLMs. Eadie-Hofstee (A–C) and Michaelis-Menten (D–F) plots depict
1-hydroxymidazolam formation in the presence of water and 0.1, 1, or 2% (v/v) of
acetonitrile (ACN) (A and D), methanol (MeOH) (B and E), or ethanol (EtOH) (C
and F). Symbols denote observed values. Curves denote model-generated values.
Error bars denote S.D.s of triplicate incubations.
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than 20%, whereas concentrations 	1% underpredicted ClH by more
than 50%. Similar to (S)-warfarin, ClH for midazolam under control
conditions was within the range of observed values (5.5 versus 5.3–
7.6 ml  min1  kg1) (Thummel et al., 1996; Gorski et al., 1998;
Tsunoda et al., 1999; Isoherranen et al., 2008). Consistent with the
lack of effect on S50 and Vmax, the tested solvents at all concentrations
had a minimal to modest effect on ClH, underpredicting by 20%.
The rigorous assessment of the effects of acetonitrile and meth-
anol on (S)-warfarin ClH could be of relevance when designing in
vitro studies in which 1% concentrations are required. The
50 – 80% underprediction of (S)-warfarin ClH caused by these
solvents may provide useful information when evaluating the in-
teraction liability of new molecular entities with warfarin. Unlike
(S)-warfarin ClH, midazolam ClH was affected modestly by aceto-
nitrile, methanol, and ethanol (at most by 20%). Additional calcu-
lations showed that Clmax would have to decrease by 40% to
impact ClH by 	20%, substantiating the resilience of midazolam
1-hydroxylation to these solvents.
The current study confirmed that the differential effects of solvents
on CYP2C9 and CYP3A4/5 activity are both solvent concentration
and substrate dependent. Although identifying the mechanisms by
which acetonitrile and methanol alter (S)-warfarin kinetics was be-
yond the scope of this work, a comparison between structural features
of CYP2C9 and CYP3A4/5 provides some insight. A recent report
ranked the catalytic site of both CYP3A4 and CYP3A5 as more
flexible and promiscuous than that of CYP2C9 (Otyepka et al., 2012).
This ranking is consistent with the minimal interference of the tested
solvents on the midazolam-CYP3A4/5 interaction but marked inter-
ference of the (S)-warfarin-CYP2C9 interaction. A previous analysis
of the CYP2C9 crystal structure showed that binding of one (S)-
warfarin molecule to the substrate binding pocket led to expansion of
this pocket, facilitating binding of an additional (S)-warfarin molecule
or other ligand, such as the inhibitor fluconazole (Williams et al.,
2003). This interaction has been shown to be essential for (S)-warfarin
affinity and regioselectivity (Seifert et al., 2006), as well as access to
the heme moiety (Williams et al., 2003; Seifert et al., 2006). Whether
or not the tested solvents alter the kinetics of (S)-warfarin 7-hydroxy-
lation via alterations in substrate binding and/or enzyme topology
merit further investigation.
The current work represents the first rigorous evaluation of the
effects of common organic solvents on (S)-warfarin 7-hydroxylation
and midazolam 1-hydroxylation in a variety of enzyme sources.
Based on the criterion of 20% inhibition, acetonitrile or methanol
(0.1%) is recommended for studies involving (S)-warfarin 7-hy-
droxylation and HLMs or rCYP2C9s as enzyme sources. If higher
solvent concentrations are necessitated, a significant decrease in Vmax
should be anticipated, as much as 60% using HLMs; a significant
increase in Km should be anticipated with methanol at 2%, as much as
100%. (S)-warfarin ClH will be underpredicted, by as much as 65 and
84% with acetonitrile and methanol, respectively. Acetonitrile, meth-
anol, or ethanol (2%) is recommended for studies involving mida-
zolam 1-hydroxylation and HLMs, HIMs, or rCYP3As as enzyme
sources. All of these solvents should be expected to have only modest
effects on either kinetic parameter with HLMs, as well as midazolam
ClH. This information fills the knowledge gap regarding solvent
effects on P450 probe substrate reactions and should facilitate opti-
mization of experimental conditions. Such optimized conditions will
improve the interpretation and accuracy of in vitro-in vivo predictions
when an organic solvent is required for solubilization of substrate
and/or test molecule.
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